01
Design
By generating the reversed, complementary mRNA sequence of the acetylcholine receptor, we derive the exact mirror of the target: its complementary peptide.
For a world without autoimmune diseases
Targeted Active Therapies (TAT): complementary-peptide immunotherapies that train the immune system without weakening it.
Phase 1b
successful (safety)
Video in English · 59 s
Uto, 9 months old, back on his paws
Diagnosed with canine myasthenia gravis at just 9 months old, this Golden Retriever received three injections of CV-MG01. Within six weeks his remission was complete. More than two years later, Uto remains symptom-free and runs as he pleases.
Day 1 → Day 47
3 injections
Remission in 6 weeks
> 2 years symptom-free
The mechanism
From blockade to remission, at the molecular scale
Targeted Active Therapy induces the production of complementary antibodies that neutralize the disease-causing autoantibodies by binding to them, thereby blocking their action.
The mechanism
Three steps, one breakthrough
Whereas current treatments often suppress the entire immune system, our Targeted Active Therapy (TAT) achieves highly targeted action through a complementary peptide immunization.
The mechanism
Three steps. One breakthrough.
Where current treatments knock out the entire immune system, our Targeted Active Therapy (TAT) acts with surgical precision thanks to the complementary peptide.
From receptor mRNA to mirror peptide
auto-Abanti-auto-Ab
02
Inject
Over the course of three doses, the complementary peptide elicits the production of neutralizing antibodies in each individual patient.
03
Neutralize
These antibodies specifically bind the pathogenic auto‑antibodies, preventing them from interacting with their receptors, thereby restoring normal function at the neuromuscular junction.
“Striving for lasting remission, rather than lifelong treatment.”
A single platform, extensible to multiple autoimmune diseases — including MS, type 1 diabetes, lupus, Graves' disease (Basedow), and Hashimoto's disease.
A silent, widespread scourge
In autoimmune diseases, the immune system attacks the body’s own tissues. An estimated 5–8% of the global population — more than 400 million people — are affected. For myasthenia gravis, no definitive cure is currently available; existing therapies aim at temporary control and symptomatic relief rather than eradication of the disease.
Estimated cases by region:
0
Graves' (Basedow) disease
0
Hashimoto's disease
0
Type 1 diabetes
0
Multiple sclerosis
0
Systemic lupus
Our target
0
Myasthenia gravis
Estimated number of cases in Europe.
Credibility grounded on evidence
Successful Phase 1b
- Conducted at the UZA (Antwerp)
- 2016-2018
- Excellent safety and tolerability profile
- Indications of efficacy
75%
remission in dogs treated with 3 doses of CV-MG01
€18M
in funding channeled.
EMA · FDA
Orphan drug, EU 2009 and US 2011.
MYASTERIX
European FP7 consortium, €6M EC grant.
MYASTERIX2
Supported by the Public Service of Wallonia.
From discovery to Phase 2
See the full story2003
CuraVac was founded by Dr Stéphane Huberty, himself a myasthenia gravis patient. Soon after its inception, the company secured the patent on the complementary peptide.
2007
Publication of the study demonstrating the efficacy of the therapy in naturally-occurring myasthenia gravis in companion dogs.
2009-2011
Orphan drug designation from the EMA in Europe, followed by orphan drug designation from the FDA in the United States.
2015-2018
Phase 1b at the University Hospital of Antwerp demonstrated an excellent safety and tolerability profile, with indications of clinical efficacy.
2023-2026
First dogs treated with CV-MG01 (Uto: complete remission in 6 weeks) and "limited markets" status (veterinary medicinal product) granted by the EMA.
Where we stand today
Getting ready for Phase 2 with CV-MG02, a more potent formulation.
A team at the center of a network of experts
Our team brings together experience from the vaccine industry and academia, and is backed by a leading advisory board.
-
Dr Stéphane Huberty
Founder & CEO
Physician, himself a patient with myasthenia gravis.
-
Nicolas Havelange
Chief Operating Officer
25 years in pharmaceutical biotech, formerly GSK.
-
Dr Jean-Paul Prieels
Chief Scientific Officer
Former SVP R&D at GSK Vaccines.
Advisory board: specialists from the vaccine industry and academia support the team's strategic decisions.
Veterinary Unit
First two dogs in remission from myasthenia gravis with CuraVac's treatment
The same technology, now serving animals
75% remission in 2.4 months in dogs (versus 18% over 24 months with current standard‑of‑care treatments): CuraVac’s Veterinary Unit is adapting its platform for animal health
Discover the Veterinary UnitFunding a therapeutic breakthrough
More than 18 million euros have already been committed to one objective: eliminating myasthenia gravis first, then other autoimmune diseases.
Sources
- 75 % Grants
- 20 % Investments
- 5 % Donations
Support us with a donation
Secure donations in EUR or USD. More than $600,000 —already received from committed donors— has helped us make a difference.
Wall of support
They support CuraVac
Researchers, patients, families, donors: those who believe in our science leave a word. Add yours.
8 messages of support
Keep doing a good job!
Merci de redonner de l'espoir aux familles touchées par les maladies auto-immunes.
J'ai contribué aujourd'hui. Peu importe la somme, l'important est d'avancer ensemble vers la Phase 2.
Heel veel succes met fase 2. Wetenschap met een hart.
Continuez : la recherche a besoin de gens qui s'attaquent à la cause, pas seulement aux symptômes.
Uto's story brought tears to my eyes. Rooting for you — humans and dogs alike.
Enfin une explication du mécanisme qu'on comprend sans être scientifique. Bravo pour la clarté du site.
Ma mère vit avec une myasthénie depuis des années. Savoir qu'une équipe cherche une rémission durable, et pas seulement à soulager les symptômes, change tout pour nous.
Contact us
A question about our platform, a story to share, a wish to support the project? Write to us.
- CuraVac Europe S.A.
- Avenue de Villefranche 80, 1330 Rixensart, Belgium
- VAT number
- BE0479.403.989
- info@curavac.com
- Main office
- 9:00 - 17:30